Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales
Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual...
Medical Institutions Directed to Adhere to ‘Six Should Do’s’ and ‘Six Prohibited Behaviors’ for Academic Lectures
Medical institutions have reportedly been circulated with a “Notice on Issuing Work Tips for Medical...
China Proposes Market-Oriented Pricing for Innovative Drugs to Boost High-Quality Development
The National Healthcare Security Administration (NHSA) has unveiled a draft Notification on “Establishing a Price...
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...
Jiangsu Hengrui Receives NMPA Approval for Phase II Study of GLP-1 Agonist for Weight Loss
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales
Chinese biopharmaceutical company Innovent Biologics Inc., (HKG: 1801) has reported impressive quarterly sales figures, announcing...
Shanghai Procurement Platform Offers Price Cut Leeway to Escape ‘High-Priced Drugs’ Tag
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) platform has announced a significant policy shift regarding non-winning...
BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers
German biotechnology company BioNTech SE (NASDAQ: BNTC) and its partner Duality Biologics (Suzhou) Co., Ltd...
NMPA Reports Record 61 Innovative Medical Device Approvals in 2023
The National Medical Products Administration (NMPA) has released its 2023 medical device filings work report,...
Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion
Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...
Bayer Partners with TetraScience to Enhance Data Management in Product Development
Germany-based Bayer (ETR: BAYN) has announced a partnership with data management firm TetraScience to collect...
Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development...
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...
MSD’s Keytruda Secures 13th Indication Approval in China for Biliary Carcinoma Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced that...
Peijia Medical’s Taurus Atlas Pro Balloon Dilation Catheter Approved by NMPA for Pulmonary Valve Procedures
Peijia Medical Ltd (HKG: 9996) has announced that it has received marketing approval from the...
MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System
MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its...
Jiangsu Wuzhong Pharmaceutical Partners with SPH KDL Health to Boost Aesthetics Product AestheFill
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a...
Konruns Pharmaceutical Commences Phase III Clinical Trial for KC1036 in Esophageal Cancer
Konruns Pharmaceutical Co., Ltd (SHA: 603590), a Beijing-based pharmaceutical company, has announced the first patient...
Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with...
Abbisko Therapeutics Secures $70 Million Upfront Payment in Licensing Deal with Merck KGaA
Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has declared the successful conclusion of...